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Abstract
This symposium provided a useful forum for the discussion of issues relating to the design
and conduct of clinical trials. There is a need for greater awareness of the complexity of
modern day trials, in which a host of statistical, logistical, regulatory and ethical issues are
involved. Issues discussed ranged from the effect of sample size on the outcome, and
subgroup analysis, to defining and maintaining discrete endpoints. Some useful debate
centred on the use of meta-analysis and the current limitations of combining information from
different data sets. This brought up the subjects of trial registries and raw data repositories
for all clinical trials. Progress and relevance of the Cochrane collaboration were reviewed.
The economics of clinical trials was another important topic. Regulatory issues such as the
role of data and safety monitoring boards (DSMB) and the guidelines in place for effective
data monitoring and progress analysis were discussed. Representatives of government
organisations and industry gave both European and American perspectives. This report
however focuses specifically on the section devoted to the subject of clinical trials in
developing countries.
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Introduction
The symposium was organised by the Clinical Trials and
Evaluation Unit, Royal Brompton and Harefield NHS Trust
(UK), in collaboration with The National Heart and Lung
Institute (UK) and The Maryland Medical Research Insti-
tute (USA), and was held at the Royal College of Physi-
cians, London (UK). The theme was “Advanced issues in
the design and conduct of randomised clinical trials”.
Approximately 250 delegates attended from around the
world. It brought together key people involved at the prac-
tice end of clinical trials (co-ordinators, medical personnel,
epidemiologists), scientists, members of regulatory
bodies, industry representatives, publishers, statisticians
and data analysers. The symposium was divided into eight
sessions addressing a range of topical and challenging
issues in clinical trials: economic evaluation; use of base-
line data; innovative designs; the role of data and safety
monitoring committees; sample size issues in clinical
trials; meta-analysis as a guide to clinical practice; regula-
tory issues; and trials in developing countries.
The subject of clinical trials in developing countries was
introduced briefly during the keynote address and
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speakers, Baruch Brody and Salim Yusuf, gave their
views on ethical and organisational issues, using spe-
cific examples of trials carried out in developing coun-
tries. Richard Smith of the British Medical Journal
addressed the subject of research and the publication
of data from developing countries, highlighting the prob-
lems faced and outlining possible solutions.
Keynote address: “Clinical trials in the new
millennium”
Professor David DeMets (University of Wisconsin-Madison,
USA) outlined the role of the randomised clinical trial (RCT)
in the advancement of medical technology and therapeutics,
and how it has evolved over the 50 years since it was first
introduced. Statistical methodology and information tech-
nology have been developed to improve collation, monitor-
ing, analysis and access to the huge quantities of data
involved in today’s large international multi-centre trials.
The prospect for clinical trials has changed in recent
years. In the USA, for example, government funding has
been levelling out except in few key areas, such as breast
cancer and AIDS research. The role of industry is increas-
ing, often in partnership with academic institutions. Politi-
cal and public interest in new clinical trials is also rising.
Investors and many patient advocacy groups keenly
monitor trial activity, and new policies on trial monitoring
are being debated in the US Congress.
In this changing environment existing standards need to
be re-evaluated in particular areas of medical technology
such as medical devices, new procedures and alternative
medicine, which DeMets felt were not properly regulated.
He stressed that the development of revised standards
should not result in high costs for industry, which have
become a problem in the testing and approval of new
drugs. DeMets also pointed out emerging areas likely to
affect medical technology, such as the potential impact of
genomics: if utilised constructively, results from genomics
research could lead to the design of better, more accu-
rate, treatment strategies and efficient trials.
The situation of developing nations contrasts with this
vision of high-cost technological advancement in highly
developed westernised countries. DeMets stressed the
need to address the often complicated ethical, moral and
logistical issues involving clinical trials in these countries.
Trials in developing countries: ethical issues
Dr Baruch Brody (Baylor College of Medicine, USA)
explored the concept of medical imperialism in the
conduct of trials in developing countries. He used as a
direct example the criticisms raised of recent clinical trials
for the prevention of vertical transmission of HIV in devel-
oping countries. The criticisms highlighted could be
applied to clinical trials in general:
Injustice. Is it fair to deny a control group life saving
therapy? The proposed revision of the Declaration of
Helsinki states that the control group “should be assured
that they will not be denied access to the best treatment
otherwise available to him or her”. However there is
debate regarding the interpretation of this statement.
Brody felt that the revision would be more plausible if it
specified “….in light of the practical realities of health care
resources available in that country”. He felt this would
force the focus onto issues of justice and less on what
should be provided or actually is provided.
Coercion. If participants join a trial simply to receive treat-
ment normally unavailable, and so not on a strictly volun-
tary basis, does this imply coercion? Brody dismissed this
point, explaining that coercion generally implies a threat
and simply offering someone a great opportunity should
not be deemed unfair or coercive.
Exploitation. Is the treatment being tested unlikely ever to
be available or of real use to participants? It is generally
accepted that clinical trials should ideally be carried out in
areas where the host community is likely to benefit from a
positive outcome and where the treatment will be reason-
ably available. If not, and the results are likely to benefit
only the richer developed countries carrying out the trial,
the host population is being exploited. Should avoidance
of exploitation be an ideal, or should it be a requirement
prior to ethical approval? How stringent should the guide-
lines be? Who needs to be protected from exploitation -
the trial participants only or the whole country in question?
Brody pointed out that imposition of such long-term condi-
tions might discourage drug companies from conducting
such trials, because of the high cost of making the treat-
ment available and accessible throughout the country.
This may prevent important trials from being run. In his
view, it is the individual participants in trials who are at
highest risk of exploitation and it is their long-term welfare,
which should be of primary importance.
Comment from the audience
One delegate felt there were arguments for not getting
involved in trials in developing countries. Trialists, he said,
should be extremely cautious before considering conducting
trials in developing countries, pointing out some of the pitfalls
involved: less than ideal data collection, false reporting by
patients and theft of supplies. In reply, Brody pointed out that
the critical public health issues plaguing many third world
countries outweighed these considerations. He stated that it
should be the moral imperative of richer developed nations
to continue carrying out trials that benefit the participants in
these countries, regardless of potential pitfalls.
Challenges of trials in developing countries
Dr Salim Yusuf (McMaster University, Canada) started his
talk by giving an example from his personal experiencec
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with the EMERAS/ECLA trials carried out in South
America, which demonstrated advantages to carrying out
clinical trials in developing countries. This project showed
that simple well-organised trials paid off well above expec-
tations. With the help of local staff it resulted in excellent
quality data collection and follow-up. It was also the
impetus for setting up “with minimum funding but
maximum zeal and determination” other local projects and
spin-off studies, data registries, local evidence-based clini-
cal forums and resulted in an overall increase in clinical
awareness.
He discussed the large successful high-quality trials
carried out in developing countries such as India and
China. Conditions there may be simpler and more suitable
for certain trials than in other countries, yielding high-
quality data. He noted that, although more time was often
needed to set up these trials and to train staff, the “cleanli-
ness” of data and the diligence of follow-up could be at
least as good as that of equivalent trials in western coun-
tries. This was often due to the enthusiasm and motivation
of local staff to address the very real problems existing in
their communities.
Yusuf proposed several general issues for consideration
when attempting to design international trials involving
developing countries:
• Is the disease similar in different countries? (Epidemio-
logical data are required to answer this question.)
• Is the trial relevant to the country: are the risk factors
the same, is the treatment relevant and are the out-
comes approximately the same?
• Do the culture and infrastructure exist to carry out this
trial?
Determining the difference between “wants” and “needs”,
Yusuf felt, is crucial to providing effective health care solu-
tions in a developing country. Western nations should be
aiming to improve long-term healthcare in developing
countries rather than providing ‘quick-fix’ short-term solu-
tions. In particular, he mentioned the expansion of clinical
research organisations (CROs) into developing countries.
It is a damaging influence if they are there simply to carry
out trials as cheaply as possible, in order to maximise
profits, without real concern for the welfare of the local
population.
He made it clear that organisers of trials in developing
countries should aim to make the trials as simple as possi-
ble, and that it was crucial to understand local conditions:
geography, infrastructure limitations, traditions, social
organisation and politics, and to aim to work efficiently and
sensitively within them. Long-term commitment to the
project is essential, as is the understanding that more
hands-on input would be needed than in developed coun-
tries, at all levels of the project. Researchers should be
realistic and prepare for possibly extreme or adverse con-
ditions. Trials in developing countries should not become
a new form of neo-colonialism, however; researchers
should see their role as helping, guiding and teaching, but
not taking control.
In concluding this inspiring and passionate talk, Yusuf urged
that trials in developing countries were possible and that the
key was in the careful planning of large simple trials.
Publishing research in developing countries
Richard Smith (Chief Executive, British Medical Journal)
addressed the disparities of publishing research from the
developed compared to the developing world. He began
with the statistic that, 20 years from now, 80–90% of all
disability-adjusted life years lost would be in the develop-
ing world, as a result of the escalating levels of disease
spread in areas such as Africa, India and in Southeast
Asia. And yet by comparison only a minute fraction of rele-
vant research may be carried out in these countries (he
estimated less than 1%). What little research is done is
often carried out on the diseases of the richer developing
countries rather than the poor.
A BMJ  editors’ survey of 33 African research institutes
brought to light what researchers there considered their
biggest obstacles: poor institutional organisation, lack of
funding, hopeless career structure, lack of mentors and
support and very little research culture. In many African
nations, research is often regarded as a luxury rather than
a necessity – possible only when there is money to spare.
Regarding publishing, barriers perceived were the use of
English as the language of publication, lack of guidance in
the preparation of papers, a fear of criticism by editors of
journals in the developed world, and ignorance both of the
way journals operate and of which would be suitable for
publishing their research. They perceived a bias against
research from their part of the world and felt that reviewers
often did not understand the special difficulties of carrying
out research in the developing world.
He predicted that, in 5 years, publication of most research
(including clinical trials) would not take place in the paper
form of journals, but on forums such as PubMed Central
(http://pubmedcentral.nih.gov) or BioMed Central (http://
biomedcentral.com). He felt sure some version of this form
of publishing would “play out” in the long run.
Smith felt that, at present, most publishers were unfairly
exploiting the system and actually devaluing it by breaking
up research information. In the current system researchers
do 99% of the work involved in trials, then edit and review
manuscripts, and the copyright is then handed over to the
journal. The academic community must then often pay
high prices to access and archive this research informa-
tion. He felt that this was less than ideal, “sucking out ofthe system without giving anything back”. In developing
countries this high cost of subscription makes research
information access even more difficult.
The World Wide Web has facilitated accessibility to data
from different sources simply and cheaply. Sites such as
PubMed Central and BioMed Central would potentially
allow all research data to become easily available regard-
less of journal bias. An editor would not have to consider
the journals’ readership, issue lengths and other matters
unrelated to the research itself. This is good news for
research from the developed world, which sometimes is of
interest only to readers in the originating region and which
may not meet the needs of a general readership. The
material would be freely available to everyone with Internet
access – the availability of which is growing exponentially
around the world.
Journals, he felt, could become more accessible to the
developing world: by making Internet access free to users
in poorer regions, and by having regional editions (where
feasible). Smith also proposed that the standards applica-
ble to research, and in particular to trials, in the developed
world could differ for research generated in less devel-
oped countries. Such trials are being carried out under dif-
ferent conditions and their aims are likely to be different.
He pointed out, for example, that research done in com-
munity medicine is evaluated differently from laboratory
research. This does not have to imply lower standards -
just different sets. Despite this proposal, Smith suggested
that all trials published should conform to certain basic
ethical guidelines and information should be fully dis-
closed.
Conclusion
This report has focused mainly on issues surrounding clini-
cal trials in developing countries. Although this was only
one of the many important issues raised at this sympo-
sium, it is nevertheless an important and complicated
subject deserving attention and discussion. One point
raised many times was the huge disparity in resources
devoted to clinical trials in the developed world compared
with those in the underdeveloped world, where the level of
effective and realistic treatment for major population-
threatening diseases lags far behind acceptable levels.
Further discussion of these issues at future symposia
should help to target trial resources more fairly towards
areas of greatest need.
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